A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD.
The goals of the study are to learn:
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Trialsites@msd.com1-888-577-8839
Irvine, California 92614, United States
949-753-1663
New Haven, Connecticut 06510, United States
Fort Myers, Florida 33912, United States
Miami Lakes, Florida 33016, United States
Elk Grove Village, Illinois 60007, United States
Ridgewood, New Jersey 07450, United States
Springfield, New Jersey 07081, United States
Albany, New York 12208, United States
Cypress, Texas 77429, United States
Ciudad de Buenos Aires, Buenos Aires F.D. C1015ABO, Argentina
+5491143720308
Ciudad de Buenos Aires, Buenos Aires F.D. C1431FWO, Argentina
+5401152990000
Caba, C1428AQK, Argentina
+541157773200
Macquarie Park, New South Wales 2113, Australia
Brussels, Bruxelles-Capitale, Region de 1200, Belgium
ÅŒbu, Aichi-ken 474-8511, Japan
Kawasaki, Kanagawa 210-0852, Japan
Kanzaki-gun, Saga-ken 8420192, Japan
+81-952-52-3231
Okayama, 700-8557, Japan
's-Hertogenbosch, North Brabant 5223 LA, Netherlands
Singapore, Central Singapore 308433, Singapore
Aberdeen, Aberdeen City AB25 2XE, United Kingdom
Edinburgh, Edinburgh, City of EH12 5PJ, United Kingdom
London, London, City of NW1 2PG, United Kingdom
562-606-5999
949-265-1612
909-792-9007
415-353-3585
714-542-3008
203-764-8100
561-968-2933
239-939-7777
407-500-5252
407-680-0534
305-825-6588
239-529-6780
727-849-4131
352-629-5800
407-337-3000
813-353-9613
813-800-5252
352-775-1000
407-916-0060
404-537-1281
847-593-8553
617-699-6927
636-220-1200
201-850-4622
973-850-4622
732-341-9500
518-426-0575
845-674-9398
917-672-3275
704-364-4000
216-245-6556
330-493-1118
610-277-8073
409-331-6040
949-491-0710
+61408455183
+61289607788
61394962181
+61395976568
+3227641779
+32 16 34 75 90
+3256636363
613-702-1000
4164804551
4166032581
5144003903
+81-562-46-2311
+81-47-473-1281
+81-44-366-8900
+81-59-231-5246
+81-86-422-0753
+81-72-850-8692
+81-3-3342-6111
+81-43-307-8500
+81-92-642-5774
+81-86-737-3000
+0203017170
+0203017170
+0203017170
'+6563306363
+6562566011
+82222908374
+82234101233
+82269861792
+34937365050
+34677440680
+34933160778
+34626001165
+4401313530233
+4401313530233
+44 (0) 2382318757
020 3448 4531
+441865902135
01225 476420
0121 655 016